Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2010
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (15,477,310)	$ (25,712,343)	$ 10,483,429
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	533,468	531,316	516,117
Issuance of common stock, warrants and options for services	527,207	214,123	1,241,026
Issuance of convertible notes and preferred stock in legal settlment		9,000,000
Amortization of loan premium			(3,282)
Extension of options issued to consultants	54,789	30,186	15,477
Extension of options issued to employees	36,990	105,802	212,444
Employee option cost	2,229,326	1,535,329	1,316,399
Common stock contributed to 401 (k) plan	154,516	150,865	112,325
Impairment loss on abandonment of patents	44,921	9,016	13,877
Loss on retired equipment	9,399	2,828	2,323
Deferred rent		(3,699)	(6,080)
Gain on derivative instruments	(1,911,683)	(4,432,148)	(28,843,772)
(Increase)/decrease in assets:
Deposits		(1,670,917)	1,585,064
Receivables	298,723	(457,337)
Deferred rent	598,714	629,682	955,842
Prepaid expenses	775,823	(1,729,812)	(258,747)
Inventory used for R&D and manufacturing	186,698	(94,948)	(1,076,760)
Increase/(decrease) in liabilities:
Accounts payable	(168,463)	(788,254)	693,799
Accrued expenses	(99,006)	147,919	125,031
Deferred revenue	1,500		125,000
Due to employees	(2,611)	(23,019)	(3,719)
Deferred rent	11,986
Deposits held	5,000		(10,000)
Net cash used in operating activities	(12,190,013)	(22,555,411)	(12,804,207)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additional investment in manufacturing facility			(32,059)
Decrease in restricted cash		21,357	47,195
Purchases of equipment	(54,637)	(216,761)	(493,736)
Expenditures for Patent costs	(78,959)	(122,706)	(25,340)
NET CASH USED IN INVESTING ACTIVITIES	(133,596)	(318,110)	(503,940)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	14,289,518	3,936,284
Proceeds from exercise of warrants and stock options	2,664,539	679,588	6,308,874
Payment for repurchase of preferred stock		(4,050,000)
Payments on convertible debt	(4,950,000)
NET CASH PROVIDED BY FINANCING ACTIVITIES	12,004,057	565,872	6,308,874
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(319,552)	(22,307,649)	(6,999,273)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	4,260,594	26,568,243	33,567,516
CASH AND CASH EQUIVALENTS, END OF PERIOD	3,941,042	4,260,594	26,568,243
ISSUANCE OF WARRANTS:
Increase in derivative liabilities	(6,706,667)
Decrease in additional paid-in capital	6,706,667
Total
ISSUANCE OF ADDITIONAL SHARES
Increase in common stock	(8,333)
Increase in additional paid-in capital	(241,667)
Decrease in additional paid-in capital	250,000
Total
EXERCISE OF DERIVATIVE LIABILITIES:
Decrease in derivative liabilities	122,367	202,830	5,510,490
Increase in additional paid-in capital	(122,367)	(202,830)	(5,510,490)
Total
MODIFICATION OF WARRANTS:
Increase in additional paid-in capital	(325,620)	(1,068,369)	(1,532,456)
Decrease in additional paid-in capital	325,620	1,068,369	1,532,456
Total
INDUCEMENT WARRANTS:
Increase in additional paid-in capital	(1,593,000)
Decrease in additional paid-in capital	1,593,000
Total
ISSUANCE OF COMMON STOCK FOR PREPAID SERVICES:
Increase in additional paid-in capital	(53,333)
Increase in prepaid expenses	53,333
Total
PATENT COSTS INCLUDED IN ACCOUNTS PAYABLE
Increase in patent costs	22,379	28,531
Increase in accounts payable	(22,379)	(28,531)
Total
EQUIPMENT COSTS INCLUDED IN ACCOUNTS PAYABLE:
Increase in research and office equipment		1,291	10,436
Increase in accounts payable for Equipment costs		(1,291)	(10,436)
Total
ADOPTION OF ASC 815-40:
Increase in derivative liabilities			(6,186,343)
Increase in accumulated deficit			6,186,343
Total
DISMISSAL OF LIABILITY FOR OVERPAYMENT
Decrease in accrued expenses		81,395
Increase in additional paid-in-capital		(81,395)
Total
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash expenditures for interest expense	$ 377,715	$ 195,980	$ 162,326